Ulipristal Acetate is a selective progesterone receptor modulator with anti-progesterone activity. Ulipristal binds to the progesterone receptor (PR), thereby inhibiting PR-mediated gene expression, and interfering with progesterone activity in the reproductive system. As a result, Ulipristal Acetate may suppress the growth of uterine leiomyomatosis. Furthermore, by inhibiting or delaying ovulation and effecting endometrial tissue, ulipristal can be used as an emergency contraception. As emergency birth control it should be used within 120 hours of sex. For fibroids it may be taken for up to six months.

Function

Ulipristal acetate belongs to selective progesterone receptor modulators, antagonistic and agonistic effect on progesterone receptor. It and the body of progesterone receptor binding to prevent progesterone and progesterone receptors. Acetic acid of his efficacy depends on our delivery time in the menstrual cycle. Delivery in mid follicular hyperplasia may inhibit folliculogenesis and reduce the concentration of estradiol. Corpus luteum of early administration of not obvious delay of endometrial maturation, but can make the endometrial thickness reduction of 0.6 ± 2.2mm (mean ± SD).